These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
581 related articles for article (PubMed ID: 25213591)
1. Dimethyl fumarate for relapsing-remitting multiple sclerosis. Drug Ther Bull; 2014 Sep; 52(9):105-8. PubMed ID: 25213591 [TBL] [Abstract][Full Text] [Related]
2. Dimethyl fumarate (Tecfidera) for multiple sclerosis. Med Lett Drugs Ther; 2013 Jun; 55(1418):45-7. PubMed ID: 24662841 [No Abstract] [Full Text] [Related]
3. Oral disease-modifying therapies for relapsing-remitting multiple sclerosis. Thomas RH; Wakefield RA Am J Health Syst Pharm; 2015 Jan; 72(1):25-38. PubMed ID: 25511835 [TBL] [Abstract][Full Text] [Related]
4. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. Fox RJ; Miller DH; Phillips JT; Hutchinson M; Havrdova E; Kita M; Yang M; Raghupathi K; Novas M; Sweetser MT; Viglietta V; Dawson KT; N Engl J Med; 2012 Sep; 367(12):1087-97. PubMed ID: 22992072 [TBL] [Abstract][Full Text] [Related]
7. Dimethyl fumarate for multiple sclerosis. Xu Z; Zhang F; Sun F; Gu K; Dong S; He D Cochrane Database Syst Rev; 2015 Apr; 2015(4):CD011076. PubMed ID: 25900414 [TBL] [Abstract][Full Text] [Related]
8. Effects of BG-12 (dimethyl fumarate) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: findings from the CONFIRM study. Kita M; Fox RJ; Phillips JT; Hutchinson M; Havrdova E; Sarda SP; Agarwal S; Kong J; Zhang A; Viglietta V; Sheikh SI; Seidman E; Dawson KT Mult Scler; 2014 Feb; 20(2):253-7. PubMed ID: 24150778 [TBL] [Abstract][Full Text] [Related]
9. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. Gold R; Kappos L; Arnold DL; Bar-Or A; Giovannoni G; Selmaj K; Tornatore C; Sweetser MT; Yang M; Sheikh SI; Dawson KT; N Engl J Med; 2012 Sep; 367(12):1098-107. PubMed ID: 22992073 [TBL] [Abstract][Full Text] [Related]
13. Dimethyl fumarate (BG-12) for the treatment of multiple sclerosis. Stangel M; Linker RA Expert Rev Clin Pharmacol; 2013 Jul; 6(4):355-62. PubMed ID: 23927662 [TBL] [Abstract][Full Text] [Related]
14. Tecfidera(®): an approach for repurposing. Spencer RP Pharm Pat Anal; 2014 Mar; 3(2):183-98. PubMed ID: 24588595 [TBL] [Abstract][Full Text] [Related]
15. Quality of life outcomes with BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: the DEFINE study. Kappos L; Gold R; Arnold DL; Bar-Or A; Giovannoni G; Selmaj K; Sarda SP; Agarwal S; Zhang A; Sheikh SI; Seidman E; Dawson KT Mult Scler; 2014 Feb; 20(2):243-52. PubMed ID: 24150779 [TBL] [Abstract][Full Text] [Related]
16. Diroximel Fumarate in Relapsing Forms of Multiple Sclerosis: A Profile of Its Use. Paik J CNS Drugs; 2021 Jun; 35(6):691-700. PubMed ID: 34057708 [TBL] [Abstract][Full Text] [Related]
17. Current management of relapsing-remitting multiple sclerosis. Sedal L; Wilson IB; McDonald EA Intern Med J; 2014 Oct; 44(10):950-7. PubMed ID: 25302718 [TBL] [Abstract][Full Text] [Related]
18. [Dimethyl fumarate (tecfidera) is the first line treatment choice in patients with remitting multiple sclerosis]. Shmidt TE Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(11):140-145. PubMed ID: 29265100 [TBL] [Abstract][Full Text] [Related]
19. Dimethyl fumarate (Tecfidera): a new oral agent for multiple sclerosis. Venci JV; Gandhi MA Ann Pharmacother; 2013 Dec; 47(12):1697-702. PubMed ID: 24259625 [TBL] [Abstract][Full Text] [Related]
20. Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis. Kalincik T; Kubala Havrdova E; Horakova D; Izquierdo G; Prat A; Girard M; Duquette P; Grammond P; Onofrj M; Lugaresi A; Ozakbas S; Kappos L; Kuhle J; Terzi M; Lechner-Scott J; Boz C; Grand'Maison F; Prevost J; Sola P; Ferraro D; Granella F; Trojano M; Bergamaschi R; Pucci E; Turkoglu R; McCombe PA; Pesch VV; Van Wijmeersch B; Solaro C; Ramo-Tello C; Slee M; Alroughani R; Yamout B; Shaygannejad V; Spitaleri D; Sánchez-Menoyo JL; Ampapa R; Hodgkinson S; Karabudak R; Butler E; Vucic S; Jokubaitis V; Spelman T; Butzkueven H J Neurol Neurosurg Psychiatry; 2019 Apr; 90(4):458-468. PubMed ID: 30636699 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]